J&J, Genmab strengthen case for Darzalex in frontline multiple myeloma with fresh slate of PhIII data
J&J and Genmab offered a snapshot of the Phase III data that got Darzalex its priority review for frontline use late last week, highlighting how adding the blockbuster multiple myeloma drug to a chemotherapy regimen improved the complete response rate. The partners are now ready to expound on the full extent of that benefit with some numbers on progression-free survival.
The results of the CASSIOPEIA study were published in The Lancet amid a flood of data from ASCO, where Sanofi also delineated a case for its rival anti-CD38 therapy, isatuximab, by comparing a combo with pomalidomide and dexamethasone against the chemo/corticosteroid alone.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
